Ancilia Biosciences Selected to Receive $3 Million Award from ARPA-H’s Sprint for Women’s Health Ancilia has been awarded $3M from the prestigious ARPA-H Sprint for Women’s Health to develop a novel therapy for bacterial vaginosis through IND filing.

Ancilia Biosciences Announces Closing of $4.2 Million Financing Ancilia raised $4.2M to leverage CRISPR’s natural function to create bacterial therapies with immunity against the viruses that limit their effectiveness.